Navire Pharma Inc., a BridgeBio company
3 clinical trials · Sponsor
◉ Watch Navire Pharma Inc., a BridgeBio company
| Record | Firm | Date |
|---|---|---|
| SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation (NCT05375084) | Navire Pharma Inc., a BridgeBio company | 2022-10-20 |
| SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (NCT05480865) | Navire Pharma Inc., a BridgeBio company | 2022-07-06 |
| First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors (NCT04528836) | Navire Pharma Inc., a BridgeBio company | 2020-11-12 |
Track Navire Pharma Inc., a BridgeBio company automatically
Every clearance here is in the API, with alerts when new ones post.